LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Aktien・Editas Medicine Inc
Search

Editas Medicine Inc

Open

BrancheGesundheitswesen

2.93 -3.93

Buy

Kursupdate 12. Mai 2026, 19:01 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.9

Max

3.06

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

-5.6M

Verkäufe

17M

25M

EPS

-0.06

Gewinnspanne

-22.715

Angestellte

87

EBITDA

17M

-5.3M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+88.56% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

67M

294M

Vorheriger Eröffnungskurs

6.86

Vorheriger Schlusskurs

2.93

Nachrichtenstimmung

By Acuity

8%

92%

8 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.33 / 1.54 Unterstützung & Widerstand

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

DJ

Lesen

11. Mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

DJ

Lesen

11. Mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

DJ

Lesen

11. Mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

DJ

Lesen

11. Mai 2026, 22:32 UTC

Ergebnisse

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

DJ

Lesen

11. Mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

DJ

Lesen

11. Mai 2026, 21:49 UTC

Ergebnisse

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

DJ

Lesen

11. Mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

DJ

Lesen

11. Mai 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

DJ

Lesen

11. Mai 2026, 21:23 UTC

Akquisitionen, Fusionen, Übernahmen

CSG Systems Sale to NEC Gets CFIUS Clearance

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv 1Q Loss/Shr $2.35 >OVV

DJ

Lesen

11. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Lesen

11. Mai 2026, 20:44 UTC

Ergebnisse

Steris: Board Approves New $1B Shr Repurchase Program >STE

DJ

Lesen

11. Mai 2026, 20:43 UTC

Ergebnisse

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Loss/Shr $1.52 >CLSK

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Rev $136.4M >CLSK

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Cont Ops EPS $2.24 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Rev $1.6B >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Adj EPS $2.83 >STE

DJ

Lesen

11. Mai 2026, 20:22 UTC

Heiße Aktien

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

DJ

Lesen

11. Mai 2026, 19:37 UTC

Ergebnisse

More Bad News at KKR's Private Credit Fund -- Barrons.com

DJ

Lesen

11. Mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

DJ

Lesen

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

88.56% Vorteil

12-Monats-Prognose

Durchschnitt 5.77 USD  88.56%

Hoch 15 USD

Tief 3 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

5

Buy

3

Halten

2

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Editas Medicine Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.33 / 1.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Mittelfristig

Neutral Evidence

The bullish and bearish events are balanced.

Langfristig

No Evidence

There are no events.

Stimmung

By Acuity

8 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

987.98

↑ +2.24%

JNJ

Johnson and Johnson

224.37

↑ +1.35%

ABBV

AbbVie Inc

207.85

↑ +2.48%

UNH

UnitedHealth Group Inc

396.24

↑ +3.1%

AZN

AstraZeneca PLC

184.48

↑ +1.46%
help-icon Live chat